N4-Acetylcytidine Boosts Synthetic mRNA Translation

In a groundbreaking advancement for synthetic mRNA therapeutics, recent research unveils how the chemical nature of nucleotide modifications profoundly influences ribosome behavior during translation. This study focuses on comparing two pivotal modifications, N4-acetylcytidine (ac4C) and N1-methylpseudouridine (m1Ψ), elucidating their differential impacts on translation efficiency, fidelity, ribosome dynamics, and immune evasion. The work not only deepens our understanding of mRNA translation but also offers critical insights for the design of next-generation mRNA-based medicines.

Translation of mRNA into proteins is tightly regulated at multiple levels, with ribosomal elongation being a vital phase susceptible to disruption by nucleotide modifications. Ribosome collisions, a phenomenon arising when trailing ribosomes encounter stalled ones, can activate ribosome quality control (RQC) pathways and cause +1 frameshifting errors, which lead to truncated or aberrant protein products. Such frameshifting may generate neoantigens, potentially triggering unintended immune responses. This study presents compelling evidence that m1Ψ modifications incite substantial ribosome collisions and frameshifting on synthetic mRNAs, particularly within uridine-rich sequences.

Through experiments utilizing in vitro translation assays with rabbit reticulocyte lysates and mammalian cell transfections, the study demonstrates that m1Ψ significantly increases +1 frameshifting on mRNAs containing tandem uridine motifs, marked notably by the presence of full-length firefly luciferase (FLuc) protein from frameshift-dependent reporter constructs. Contrastingly, ac4C, although it slows translation elongation modestly, does not elicit elevated frameshifting or ribosome collision markers in cytidine-rich contexts, highlighting a striking functional divergence between these two modifications.

High-resolution ribosome profiling in cells transfected with FLuc reporters reveals that m1Ψ-modified mRNAs accumulate ribosomes at uridine-rich stretches, suggesting pronounced pausing and ribosome stacking. These pauses are accompanied by distinct P-site density peaks separated by approximately 31 nucleotides, indicative of tightly packed ribosome queues. In contrast, ac4C-modified mRNAs show uniform ribosome distribution, reflecting smoother elongation dynamics without substantial stalling or collisions.

The molecular underpinnings of these differential effects appear rooted in the conformational constraints imposed by each modification on the ribosomal decoding center. Acetylation at the N4 position in ac4C reinforces the canonical Watson-Crick base pairing geometry, thus preserving elongation fidelity and minimizing translational disruptions. In stark contrast, m1Ψ’s altered ribose conformation destabilizes normal decoding interactions upon translocation to the ribosome’s P-site, thereby increasing translational dwell times and the probability of errors such as frameshifting.

Interestingly, both ac4C and m1Ψ confer substantial evasion from innate immune sensing, despite modifying different nucleotides—cytidine and uridine, respectively. The mechanism appears linked to their shared resistance to RNase-T2-mediated cleavage, which prevents the generation of short nucleotide fragments that ordinarily provoke Toll-like receptor (TLR) mediated immune activation. This discovery expands the conceptual framework of immune evasion in modified RNA, which has traditionally emphasized uridine substitutions.

The study introduces a conceptual model termed ‘braking upon modified position’ (BUMP), which describes how nucleotide modifications introduce localized elongation slowdowns that manifest as ribosomal traffic jams. Depending on the chemical nature of the modification, these ‘bumps’ can range from mild decelerations supporting faithful translation to severe stalls that incite RQC and translational errors. Unmodified mRNAs, in this context, are fast but prone to initiate stress responses through phosphorylation of eIF2α, which dampens protein synthesis.

From a therapeutic perspective, these findings underscore the necessity of tailoring mRNA modifications to specific clinical needs. m1Ψ, with its robust translation despite slower elongation and its potential to induce neoantigens via frameshifting, remains advantageous in vaccine contexts where immune stimulation is desirable. Conversely, ac4C offers a compelling alternative when high protein yield with pristine accuracy is paramount, such as in protein replacement therapies where unintended immune responses or aberrant products must be minimized.

The implications of this research reverberate across the mRNA therapeutic landscape, as the balance between translation speed, accuracy, and immunogenicity becomes a design axis for synthetic mRNA optimization. The nuanced interplay between chemical modifications and ribosomal dynamics eloquently reveals why uniform substitution of canonical nucleotides in synthetic transcripts can unsettle finely tuned evolutionary mechanisms governing codon usage and translational fidelity.

Moreover, the identification of sequences prone to frameshifting, such as proline-rich dicodons, and how ac4C can potentially stabilize decoding in these regions, highlights the importance of considering local nucleotide context. This insight opens avenues for strategic codon engineering combined with precise nucleotide modifications to further enhance translational output fidelity.

By systematically integrating biochemical assays, ribosome profiling, and protein analysis across multiple biological systems, the researchers provide a comprehensive mechanistic framework linking chemical nucleotide alterations to functional translation outcomes. Their pioneering ‘BUMP’ paradigm not only harmonizes disparate observations but also charts a path for rational design of synthetic mRNAs capable of balancing immunogenicity, fidelity, and protein yield.

In conclusion, this study sets a new benchmark in our understanding of how synthetic mRNA modifications govern translational behavior. It advocates for a shift from viewing nucleotide alterations merely as immune evasion tools to recognizing their profound roles in modulating ribosome traffic and translation quality. As mRNA therapeutics venture into increasingly complex clinical territories, such mechanistic clarity will be indispensable in crafting safer, more efficacious, and finely tuned therapeutic agents that harness the full potential of RNA biology.